ATE501278T1 - METHOD OF USING IL-21 - Google Patents
METHOD OF USING IL-21Info
- Publication number
- ATE501278T1 ATE501278T1 AT06792239T AT06792239T ATE501278T1 AT E501278 T1 ATE501278 T1 AT E501278T1 AT 06792239 T AT06792239 T AT 06792239T AT 06792239 T AT06792239 T AT 06792239T AT E501278 T1 ATE501278 T1 AT E501278T1
- Authority
- AT
- Austria
- Prior art keywords
- individual
- predicting
- therapy
- patient
- detecting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
There is provided an in vitro method of predicting a differential therapeutic response to IL-21 in an individual in need of IL-21 therapy, comprising detecting, in a biological sample from the patient, an allelic variant of the individual's IL-21 receptor gene.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71938805P | 2005-09-22 | 2005-09-22 | |
PCT/EP2006/009239 WO2007039147A1 (en) | 2005-09-22 | 2006-09-22 | Methods of using il-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE501278T1 true ATE501278T1 (en) | 2011-03-15 |
Family
ID=37649383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06792239T ATE501278T1 (en) | 2005-09-22 | 2006-09-22 | METHOD OF USING IL-21 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20070111239A1 (en) |
EP (2) | EP1937838B1 (en) |
JP (1) | JP5208746B2 (en) |
AT (1) | ATE501278T1 (en) |
AU (1) | AU2006299141B2 (en) |
CA (1) | CA2620338A1 (en) |
DE (1) | DE602006020601D1 (en) |
ES (1) | ES2360728T3 (en) |
IL (1) | IL189597A (en) |
WO (1) | WO2007039147A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1848819A4 (en) * | 2005-02-16 | 2010-01-06 | Genetic Technologies Ltd | Methods of genetic analysis involving the amplification of complementary duplicons |
ES2360728T3 (en) * | 2005-09-22 | 2011-06-08 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | METHODS OF USE OF IL-21. |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69322266T2 (en) | 1992-04-03 | 1999-06-02 | Perkin Elmer Corp | SAMPLES COMPOSITION AND METHOD |
US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
US5547835A (en) | 1993-01-07 | 1996-08-20 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
US5571676A (en) | 1995-06-07 | 1996-11-05 | Ig Laboratories, Inc. | Method for mismatch-directed in vitro DNA sequencing |
US5773346A (en) | 1995-12-06 | 1998-06-30 | Micron Technology, Inc. | Semiconductor processing method of forming a buried contact |
US6803451B2 (en) | 1998-09-23 | 2004-10-12 | Zymogenetics, Inc. | Cytokine receptor zalpha11 polypeptides |
US6576744B1 (en) | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
AU2003251633A1 (en) * | 2002-07-01 | 2004-01-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Il-21 as a regulator of immunoglobin production |
EP1782823A3 (en) * | 2002-10-11 | 2007-05-16 | Novo Nordisk A/S | IL-21 peptides and nucleic acids |
BR0315134A (en) * | 2002-10-11 | 2005-08-16 | Novo Nordisk As | Uses of il-21 and an il-21 Polypeptide |
JP4664684B2 (en) | 2002-12-13 | 2011-04-06 | ザイモジェネティクス, インコーポレイテッド | Production of IL-21 in prokaryotic hosts |
ES2360728T3 (en) * | 2005-09-22 | 2011-06-08 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | METHODS OF USE OF IL-21. |
-
2006
- 2006-09-22 ES ES06792239T patent/ES2360728T3/en active Active
- 2006-09-22 AU AU2006299141A patent/AU2006299141B2/en not_active Ceased
- 2006-09-22 CA CA002620338A patent/CA2620338A1/en not_active Abandoned
- 2006-09-22 EP EP06792239A patent/EP1937838B1/en not_active Not-in-force
- 2006-09-22 US US11/534,332 patent/US20070111239A1/en not_active Abandoned
- 2006-09-22 EP EP10185146A patent/EP2311995A1/en not_active Withdrawn
- 2006-09-22 JP JP2008531618A patent/JP5208746B2/en not_active Expired - Fee Related
- 2006-09-22 WO PCT/EP2006/009239 patent/WO2007039147A1/en active Application Filing
- 2006-09-22 DE DE602006020601T patent/DE602006020601D1/en active Active
- 2006-09-22 AT AT06792239T patent/ATE501278T1/en active
-
2008
- 2008-02-18 IL IL189597A patent/IL189597A/en not_active IP Right Cessation
-
2010
- 2010-06-17 US US12/817,857 patent/US20100291029A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2006299141B2 (en) | 2011-11-24 |
AU2006299141A1 (en) | 2007-04-12 |
US20100291029A1 (en) | 2010-11-18 |
US20070111239A1 (en) | 2007-05-17 |
JP5208746B2 (en) | 2013-06-12 |
IL189597A0 (en) | 2008-08-07 |
ES2360728T3 (en) | 2011-06-08 |
WO2007039147A1 (en) | 2007-04-12 |
JP2009508506A (en) | 2009-03-05 |
EP1937838B1 (en) | 2011-03-09 |
CA2620338A1 (en) | 2007-04-12 |
IL189597A (en) | 2012-06-28 |
EP2311995A1 (en) | 2011-04-20 |
EP1937838A1 (en) | 2008-07-02 |
DE602006020601D1 (en) | 2011-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS51859B (en) | Method for predicting the response to a treatment with a her dimerization inhibitor | |
ATE390925T1 (en) | USE OF SUBSTITUTED QUINOLINE DERIVATIVES FOR THE TREATMENT OF DRUG RESISTANT MYCOBACTERIAL DISEASES | |
EP2239262A3 (en) | Fused ring heterocycle kinase modulators | |
ATE406575T1 (en) | METHOD FOR DETECTING DRUG SENSITIVITY IN PATIENTS WITH INFLAMMATORY DISEASES | |
ATE406351T1 (en) | CONDENSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | |
NO20052955L (en) | Treatment of Huntington's disease with EPA | |
CY2015025I1 (en) | METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | |
BR0111125A (en) | Nrg-2 Nucleic Acid Molecules, Polypeptides, and Diagnostic and Therapeutic Methods | |
DE60323300D1 (en) | Apparatus for the early detection of ischemic heart disease | |
MX2007006529A (en) | Selecting patients for therapy with a her inhibitor. | |
MX2009003562A (en) | Elisa for vegf. | |
ATE329610T1 (en) | ANTI-APRIL ANTIBODIES AND HYBRIDOMA CELLS | |
ATE359508T1 (en) | SCREENING METHODS USING ZEBRAFISH AND THE BLOOD-BRAIN BARRIER | |
DE602005008325D1 (en) | Quantification of enzyme activity by means of planar waveguides | |
DE602006012995D1 (en) | BREAST CANCER DIAGNOSTIC PROCEDURE | |
DK2005162T3 (en) | screening Method | |
Ardakani et al. | Quantifying the correlation between spatially defined oxygen gradients and cell fate in an engineered three-dimensional culture model | |
ATE527378T1 (en) | ANTISENSE MODULATION OF P38 MITOGEN-ACTIVATED PROTEIN KINASE EXPRESSION | |
DK1526840T3 (en) | Nanoparticles for DNA administration to a target organ | |
DE602005002673D1 (en) | Nucleotide sequence variation in the NS5A gene as a marker | |
TW200734638A (en) | Method for the diagnosis of thromboembolic and coronary heart diseases | |
ATE501278T1 (en) | METHOD OF USING IL-21 | |
ATE508201T1 (en) | METHOD FOR GENERATING A GENETICALLY MODIFIED ORGANISM FOR ACTIVE SUBSTANCE SCREENING | |
EP2508886A3 (en) | Means and methods for classifying samples of multiple sclerosis patients | |
DK1991696T3 (en) | Method for Diagnosing a Plant in Patients with Disseminated Sclerosis for Interferon Therapy Susceptibility and for Diagnosing Disseminated Sclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1937838 Country of ref document: EP |